FDA expands the indication of Vascepa (icosapent ethyl) capsules to reduce the risk of cardiovascular events as an adjunct to maximally tolerated statin therapy in high-risk adult patients with elevated triglyceride levels. It is a fish oil-derived omega-3 fatty acid product indicated to reduce the
Read more: FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups